Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients
Transarterial chemotherapy (TACE) is the standard treatment for patients with intermediate-stage hepatocellular carcinoma (HCC), defined as large, unresectable, or multinodular HCC in patients with good functional performance. The definition of TACE refractoriness is not well established. Generally,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Gastrointestinal Intervention
2021-10-01
|
| Series: | International Journal of Gastrointestinal Intervention |
| Subjects: | |
| Online Access: | http://journaleditor.inforang.com/journal/view.html?doi=10.18528/ijgii210046 |
| _version_ | 1818395152919560192 |
|---|---|
| author | Hansung Kang Hye Won Lee |
| author_facet | Hansung Kang Hye Won Lee |
| author_sort | Hansung Kang |
| collection | DOAJ |
| description | Transarterial chemotherapy (TACE) is the standard treatment for patients with intermediate-stage hepatocellular carcinoma (HCC), defined as large, unresectable, or multinodular HCC in patients with good functional performance. The definition of TACE refractoriness is not well established. Generally, TACE refractoriness is defined as an insufficient response after two or more consecutive TACE. An increase in the number of liver lesions, continuously elevated tumor markers, vascular invasion, and extrahepatic spread also suggest TACE refractoriness. Timely switching to systemic therapy for TACE refractoriness should be considered to improve the outcome. Although data are sparse, the combination of anti-angiogenic and immune checkpoint inhibitor therapies shows promise for TACE-refractory patients. In this article, we review the role of systemic therapy in TACE refractory patients with HCC. |
| first_indexed | 2024-12-14T06:12:34Z |
| format | Article |
| id | doaj.art-b84bf7373d5640bd9ee6cf43286ffdd4 |
| institution | Directory Open Access Journal |
| issn | 2636-0004 |
| language | English |
| last_indexed | 2024-12-14T06:12:34Z |
| publishDate | 2021-10-01 |
| publisher | Society of Gastrointestinal Intervention |
| record_format | Article |
| series | International Journal of Gastrointestinal Intervention |
| spelling | doaj.art-b84bf7373d5640bd9ee6cf43286ffdd42022-12-21T23:14:07ZengSociety of Gastrointestinal InterventionInternational Journal of Gastrointestinal Intervention2636-00042021-10-0110418318810.18528/ijgii210046ijgii210046Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patientsHansung Kang0Hye Won Lee1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, KoreaDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, KoreaTransarterial chemotherapy (TACE) is the standard treatment for patients with intermediate-stage hepatocellular carcinoma (HCC), defined as large, unresectable, or multinodular HCC in patients with good functional performance. The definition of TACE refractoriness is not well established. Generally, TACE refractoriness is defined as an insufficient response after two or more consecutive TACE. An increase in the number of liver lesions, continuously elevated tumor markers, vascular invasion, and extrahepatic spread also suggest TACE refractoriness. Timely switching to systemic therapy for TACE refractoriness should be considered to improve the outcome. Although data are sparse, the combination of anti-angiogenic and immune checkpoint inhibitor therapies shows promise for TACE-refractory patients. In this article, we review the role of systemic therapy in TACE refractory patients with HCC.http://journaleditor.inforang.com/journal/view.html?doi=10.18528/ijgii210046hepatocellular carcinoma; refractoriness; systemic therapy; transarterial chemotherapy |
| spellingShingle | Hansung Kang Hye Won Lee Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients International Journal of Gastrointestinal Intervention hepatocellular carcinoma; refractoriness; systemic therapy; transarterial chemotherapy |
| title | Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients |
| title_full | Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients |
| title_fullStr | Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients |
| title_full_unstemmed | Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients |
| title_short | Current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients |
| title_sort | current role of systemic therapy in transarterial chemotherapy refractory hepatocellular carcinoma patients |
| topic | hepatocellular carcinoma; refractoriness; systemic therapy; transarterial chemotherapy |
| url | http://journaleditor.inforang.com/journal/view.html?doi=10.18528/ijgii210046 |
| work_keys_str_mv | AT hansungkang currentroleofsystemictherapyintransarterialchemotherapyrefractoryhepatocellularcarcinomapatients AT hyewonlee currentroleofsystemictherapyintransarterialchemotherapyrefractoryhepatocellularcarcinomapatients |